Lexeo Therapeutics, Inc. (LXEO) Stock Forecast
LXEO analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.80 / 5 from 10 analysts
- Price target
- $20.30 average of analyst targets
- Upside to target
- +668.9% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.33
- 52-week range
- $2.63 – $10.63
LXEO analyst ratings
10 analystsNumber of analysts at each rating.
LXEO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LXEO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.32 | −$0.35 | −$0.31 | −$0.33 | +2.2% | 7 |
| Current fiscal year (2026) | −$1.20 | −$1.25 | −$1.17 | −$1.93 | +37.8% | 7 |
| Next fiscal year (2027) | −$1.37 | −$1.74 | −$1.15 | −$1.22 | −12.8% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LXEO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 10 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 10 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 9 |
LXEO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LXEO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.30 | −$0.30 | −$0.32 | −$0.32 | −$0.32 | +7.1% | 1 up · 2 down |
| Current fiscal year (2026) | −$1.14 | −$1.14 | −$1.20 | −$1.20 | −$1.20 | +5.3% | 2 up · 3 down |
| Next fiscal year (2027) | −$1.34 | −$1.34 | −$1.38 | −$1.37 | −$1.37 | +2.8% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LXEO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LXEO beat in 7 of 12.
What analysts expect from LXEO
10 analysts cover Lexeo Therapeutics; their consensus rating is strong buy (4.80 on a 1–5 scale, where 5 is a strong buy). The average price target is $20.30, 668.9% above the latest close of $2.64. Analysts expect earnings of −$1.20 per share for 2026, +37.8% from a year earlier. For 2027 the average estimate is −$1.37 per share. Lexeo Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: LXEO income statement, LXEO key metrics, LXEO chart. See the LXEO stock overview for the latest quote and news.
LXEO forecast FAQ
What is Lexeo Therapeutics's price target?
The average analyst price target for Lexeo Therapeutics is $20.30, 668.9% above the latest close of $2.64.
Is Lexeo Therapeutics a buy, hold or sell?
Of 10 analysts covering Lexeo Therapeutics, 8 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Lexeo Therapeutics's EPS forecast?
Analysts forecast −$1.20 per share for 2026 (range −$1.25 to −$1.17); for 2027 the estimate is −$1.37.
When does Lexeo Therapeutics report earnings?
Lexeo Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 before the market opens; the EPS estimate is $-0.33.
Does Lexeo Therapeutics usually beat earnings estimates?
Lexeo Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.